Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Reistone Biopharma has reported that its SHR0302 ointment met the primary goal of the Phase II MARBLE23 clinical trial in adults and adolescents with mild-to-moderate atopic dermatitis (AD).
UK TCR-focused biotech Immunocore announced that it scored a priority review with the FDA for lead drug tebentafusp.
SHANGHAI, May 13, 2021 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases, today announced the first patient has been dosed in their Phase III, global clinical trial (RSJ10333) of SHR0302, a potent and highly selective small molecule inhibitor of Janus kinase type 1 (JAK1) in patients with moderate-to-severe Atopic Dermatitis (AD). The trial is being conducted in Canada and China. The first patients enrolled were from Canada.